Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

This page is currently under revision. Read this statement from the Panel's for the most recent information on the use of tixagevimab plus cilgavimab (Evusheld) as PrEP of COVID-19.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Last Updated: December 28, 2022

For information on SARS-CoV-2 variants that were previously circulating in the United States, see the Guidelines Archive.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
WHO Label and Pango LineageBEBTIX Plus CILaBAM Plus ETECAS Plus IMDSOT
In Vitro SusceptibilitybAnticipated Clinical ActivityIn Vitro SusceptibilitybAnticipated Clinical ActivityIn Vitro SusceptibilitybAnticipated Clinical ActivityIn Vitro SusceptibilitybAnticipated Clinical ActivityIn Vitro SusceptibilitybAnticipated Clinical Activity
Omicron BA.5No changeActiveModerate reductionActiveMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron BA.4.6/BF.7 No changeActiveMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron BQ.1Marked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron BQ.1.1Marked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron XBBMarked reduction1,2Unlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active

References

  1. Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
  2. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
  3. Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. 2022. Available at: https://www.fda.gov/media/145802/download.
  4. Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2021. Available at: https://www.fda.gov/media/145611/download.
  5. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
  6. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
  7. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.